22 Apr Invenra Launches B-Body Express™ Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform
MADISON, Wis.–(BUSINESS WIRE)– Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express™ Antibody Expression service. This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra’s premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific antibodies derived from partner-provided antibody sequences. Designed to accelerate preclinical research, the service delivers speed without compromising yield, purity, or access to cutting-edge technology.
B-Body Express™ allows partners to leverage Invenra’s proven B-Body® technology using their own antibody sequences, expressed in validated formats. The service initially focuses on the highly developable 1×1 B-Body® format, alongside traditional monoclonal antibodies (mAbs). Invenra also plans to expand the B-Body Express™ service to include standardized 2×1 and 2×2 B-Body® formats in the near future.
B-Body Express™ – Validation Scale Service Features:
- Accelerated Production: High-purity B-Body® (1×1) and mAbs produced at flexible 50mL, 200mL, or 500mL scales.
- Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final DNA vector validation.
- Full Yield Delivery: Partners receive the entire antibody yield produced, maximizing research utility.
- Upcoming Format Options: Standardized 2×1 and 2×2 B-Body® formats launching soon.
- Simple Licensing Path: Includes research-use rights with a clearly defined path to commercial terms.